DRDiana Patricia Rojas

Diana Patricia Rojas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Diana Patricia Rojas has a total of 168 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global Resurgence of Cholera, 2022–2025: Epidemiological Insights from WHO Surveillance Data

    by Yurie Izawa, Juniorcaius Ikejezie, Rocio Aura Escobar Corado Waeber, Kathryn Alberti, Sandra Adele, Silvano Barbosa de Oliveira, Fatma Ben Youssef, Morgane Dominguez, Natalie Fischer, John Henry Gray, et al.

    Background: World Health Organization (WHO) reports show a sustained rise in cholera cases and deaths since 2022, with roughly half a million cases reported annually. In January 2023, WHO assigned the highest level of emergency to the global cholera resurgence. This study describes the main epidemiological features of cholera outbreaks during the ongoing resurgence.Methods: Aggregated suspected and confirmed cholera cases and deaths were compiled from official national reports from January 2022 to September 2025, with weekly and/or subnational disaggregation where available. We estimated national-level indicators of outbreak size, severity, duration, and timing to peak and control. Time-series analyses and spatial scan statistics assessed spatio-temporal patterns.Findings: More than 1·3 million cases and 17,000 deaths from 28 countries were analysed. By WHO Region, the Eastern Mediterranean Region reported the highest number of cases (671,637), while the African Region recorded the highest mortality (11,009). Of 46 identified outbreaks, 26 had case fatality ratios ≥1%. The median outbreak duration was 36 weeks (IQR 20–85), with a median time to peak of 13 weeks (IQR 5–27). Conflict-affected countries experienced longer outbreaks. Seasonal patterns were observed in parts of Africa and the Eastern Mediterranean, and space–time analyses identified multiple clusters, including cross-border spread.Interpretation: Findings indicate a period of persistent and expanding global cholera burden marked by substantial morbidity, mortality, and prolonged, often cross‑border outbreaks. Results highlight a critical window for early intervention and underscore the urgent need to establish sustainable, long‑term funding and response capacity to prepare for and respond to cholera outbreaks.


  • Open Access

    Meeting Report on an Integrated Research Agenda for Mosquito-Borne Arboviruses

    by Angela K Ulrich, Nicolina M Moua, Alison Mack, Natsuko Imai-Eaton, J Erin Staples, Angela J Mehr, Julia T Ostrowsky, Tabitha Leighton, Ana Cehovin, Petra C Fay, et al.

    The emergence and re-emergence of mosquito-borne arbovirus (MBV) diseases pose a rapidly expanding global health threat fueled by the convergence of multiple ecologic, economic, and social factors, including climate change, land use, poverty, deficiencies of water storage and sanitation, and limitations of vector control programs. On December 6, 2023, the Wellcome Trust and the University of Minnesota's Center for Infectious Disease Research and Policy held a meeting titled “An integrated approach to mosquito-borne arboviruses: a priority research agenda.” The meeting comprised presentations, panels, and facilitated discussions aimed at describing the state of the field, highlighting recent accomplishments, identifying novel strategies, and defining priority research goals and approaches for addressing MBV disease preparedness and response. This report summarizes meeting discussions in 3 key areas: the changing epidemiology of MBV disease, current and potential transmission- and disease-monitoring strategies, and evolutionary impacts on disease burden and transmission. It concludes with a list of priority strategies for research and investment in MBV disease prevention, preparedness, and control. To prepare for future epidemics of MBV diseases, research and policy will benefit from a multipathogen approach to MBVs. Building on existing knowledge and systems, these efforts must address social and ecological factors and connect with other global health agendas.


  • Top Cited Papers
    Open Access

    A Review of the Recent Epidemiology of Zika Virus Infection

    by Ingrid B. Rabe, Susan L. Hills, Joana M. Haussig, Allison T. Walker, Thais dos Santos, José Luis San Martin, Gamaliel Gutierrez, Jairo Mendez-Rico, José Cruz Rodriguez, Douglas Elizondo-Lopez, et al.

    Zika virus (ZIKV) is a flavivirus transmitted primarily by the bite of infected Aedes species mosquitoes. Although typically asymptomatic or causing mild symptoms and infrequent neurological disease in older children and adults, infection during pregnancy can result in severe congenital malformations and neurodevelopmental deficits. We conducted a review of published literature and official data sources to describe recent Zika epidemiological trends, building on WHO updates posted in 2019 and 2022. Globally, cases declined after the height of ZIKV transmission in the Americas in 2015–2016; however, transmission continues across multiple regions, with intermittent outbreaks reported. As of December 2023, there is documented evidence of current or prior autochthonous mosquito-borne ZIKV transmission in 92 countries and territories; most recently, Guinea, Mali, and Sri Lanka were included on the basis of recent or retrospective testing of specimens collected during surveillance activities or studies. The abundance of asymptomatic and mild infections and limited diagnostic testing suggest that transmission in many locations likely remains underrecognized. Public health authorities, clinicians, communities at risk, and travelers should remain alert to the possibility of ZIKV transmission and implement measures to limit the risk of infection with ZIKV and other Aedes-borne arboviruses. To strengthen surveillance for ZIKV infections and congenital disease, targeted surveillance using clear case definitions and epidemiologically appropriate laboratory testing algorithms should be applied.


  • Open Access

    Comparative Evaluation of Select Serological Assays for Zika Virus Using Blinded Reference Panels

    by Devy M. Emperador, Mars Stone, Eduard Grebe, Camille Escadafal, Honey Dave, Eve Lackritz, Cassandra Kelly-Cirino, Ingrid Rabe, Diana P. Rojas, Michael P. Busch, et al.

    In response to the 2015 Zika virus (ZIKV) epidemic that occurred in Brazil, numerous commercial serological assays have been developed for clinical and research applications. Diagnosis of recent infection in pregnant women remains challenging. Having standardized, comparative studies of ZIKV tests is important for implementing optimal diagnostic testing and disease surveillance. This is especially important for serology tests used to detect ZIKV infection given that antibodies against ZIKV can cross-react with other arboviruses in the same virus family, such as dengue virus (DENV), yellow fever virus (YFV) and West Nile virus (WNV). We looked at the sensitivity and specificity of tests detecting ZIKV antibodies (IgM, IgG) from multiple manufacturers using panels of samples previously collected with known exposure to ZIKV and other arboviruses. We found that performance of the IgM tests was highly variable, with only one test (Inbios 2.0 IgM capture ELISA) having both high sensitivity and specificity. All IgG tests showed good sensitivity; however, specificity was highly variable, with some assays giving false-positive results on samples infected by another flavivirus. Overall, the results confirmed that accurate ZIKV antibody testing is challenging, especially in specimens from regions endemic for multiple other flaviviruses, and highlight the importance of available and suitable reference samples to evaluate ZIKV diagnostics.


  • Open Access

    Prevalence of SARS-CoV-2 infection and SARS-CoV-2-specific antibody detection among healthcare workers and hospital staff of a university hospital in Colombia

    by Nohemí Caballero, María A. Nieto, David A. Suarez-Zamora, Sergio Moreno, Camila I. Remolina, Daniela Durán, Daniela Vega, Paula A. Rodríguez-Urrego, Claudia P. Gómez, Diana P. Rojas, et al.


  • Top Cited Papers
    Open Access

    A Review: Aedes-Borne Arboviral Infections, Controls and Wolbachia-Based Strategies

    by Samson T. Ogunlade, Michael T. Meehan, Adeshina I. Adekunle, Diana P. Rojas, Oyelola A. Adegboye, Emma S. McBryde

    Arthropod-borne viruses (Arboviruses) continue to generate significant health and economic burdens for people living in endemic regions. Of these viruses, some of the most important (e.g., dengue, Zika, chikungunya, and yellow fever virus), are transmitted mainly by Aedes mosquitoes. Over the years, viral infection control has targeted vector population reduction and inhibition of arboviral replication and transmission. This control includes the vector control methods which are classified into chemical, environmental, and biological methods. Some of these control methods may be largely experimental (both field and laboratory investigations) or widely practised. Perceptively, one of the biological methods of vector control, in particular, Wolbachia-based control, shows a promising control strategy for eradicating Aedes-borne arboviruses. This can either be through the artificial introduction of Wolbachia, a naturally present bacterium that impedes viral growth in mosquitoes into heterologous Aedes aegypti mosquito vectors (vectors that are not natural hosts of Wolbachia) thereby limiting arboviral transmission or via Aedes albopictus mosquitoes, which naturally harbour Wolbachia infection. These strategies are potentially undermined by the tendency of mosquitoes to lose Wolbachia infection in unfavourable weather conditions (e.g., high temperature) and the inhibitory competitive dynamics among co-circulating Wolbachia strains. The main objective of this review was to critically appraise published articles on vector control strategies and specifically highlight the use of Wolbachia-based control to suppress vector population growth or disrupt viral transmission. We retrieved studies on the control strategies for arboviral transmissions via arthropod vectors and discussed the use of Wolbachia control strategies for eradicating arboviral diseases to identify literature gaps that will be instrumental in developing models to estimate the impact of these control strategies and, in essence, the use of different Wolbachia strains and features.


  • Open Access

    Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: systematic review

    by Oyungerel Byambasuren, Claudia C Dobler, Katy Bell, Diana Patricia Rojas, Justin Clark, Mary-Louise McLaws, Paul Glasziou

    Background: Accurate seroprevalence estimates of SARS-CoV-2 in different populations could clarify the extent to which current testing strategies are identifying all active infection, and hence the true magnitude and spread of the infection. Our primary objective was to identify valid seroprevalence studies of SARS-CoV-2 infection and compare their estimates with the reported, and imputed, COVID-19 case rates within the same population at the same time point. Methods: We searched PubMed, Embase, the Cochrane COVID-19 trials, and Europe-PMC for published studies and pre-prints that reported anti-SARS-CoV-2 IgG, IgM and/or IgA antibodies for serosurveys of the general community from 1 Jan to 12 Aug 2020. Results: Of the 2199 studies identified, 170 were assessed for full text and 17 studies representing 15 regions and 118,297 subjects were includable. The seroprevalence proportions in 8 studies ranged between 1%-10%, with 5 studies under 1%, and 4 over 10% - from the notably hard-hit regions of Gangelt, Germany; Northwest Iran; Buenos Aires, Argentina; and Stockholm, Sweden. For seropositive cases who were not previously identified as COVID-19 cases, the majority had prior COVID-like symptoms. The estimated seroprevalences ranged from 0.56-717 times greater than the number of reported cumulative cases – half of the studies reported greater than 10 times more SARS-CoV-2 infections than the cumulative number of cases. Conclusions: The findings show SARS-CoV-2 seroprevalence is well below “herd immunity” in all countries studied. The estimated number of infections, however, were much greater than the number of reported cases and deaths in almost all locations. The majority of seropositive people reported prior COVID-like symptoms, suggesting that undertesting of symptomatic people may be causing a substantial under-ascertainment of SARS-CoV-2 infections. Key messages: Systematic assessment of 17-country data show SARS-CoV-2 seroprevalence is mostly less than 10% - levels well below “herd immunity”. High symptom rates in seropositive cases suggest undertesting of symptomatic people and could explain gaps between seroprevalence rates and reported cases. The estimated number of infections for majority of the studies ranged from 2-717 times greater than the number of reported cases in that region and up to 13 times greater than the cases imputed from number of reported deaths.


  • Open Access

    Delaying the COVID-19 epidemic in Australia: Evaluating the effectiveness of international travel bans

    by Adeshina Israel Adekunle, Michael Meehan, Dianna Rojas, James Trauer, Emma McBryde, Diana Rojaz Alvarez

    Following the outbreak of novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) or COVID-19 in Wuhan, China late 2019, different countries have put in place interventions such as travel ban, proper hygiene, and social distancing to slow the spread of this novel virus. We evaluated the effects of travel bans in the Australia context and projected the epidemic until May 2020. Our modelling results closely align with observed cases in Australia indicating the need for maintaining or improving on the control measures to slow down the virus.


  • Open Access

    Change in outbreak epicenter and its impact on the importation risks of COVID-19 progression: a modelling study

    by Oyelola A Adegboye, Adeshina I Adekunle, Anton Pak, Ezra Gayawan, Denis Hy Leung, Diana P Rojas, Faiz Elfaki, Emma S McBryde, Damon P Eisen

    The outbreak of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) that originated in the city of Wuhan, China has now spread to every inhabitable continent, but now theattention has shifted from China to other epicenters, especially Italy. This study explored the influence of spatial proximities and travel patterns from Italy on the further spread of SARS-CoV-2 around the globe. We showed that as the epicenter changes, the dynamics of SARS-CoV-2 spread change to reflect spatial proximities.


  • Open Access

    Dengue after Zika: characterizing impacts of Zika emergence on endemic dengue transmission

    by Rebecca K. Borchering, Angkana Huang, Luis Mier-Y-Teran-Romero, Diana Patricia P. Rojas, Isabel Rodriguez-Barraquer, Leah C. Katzelnick, Silvio D. Martinez, Gregory D. King, Stephanie C. Cinkovich, Justin Lessler, et al.

    In 2015 and 2016, Zika virus (ZIKV) swept through many Latin American countries where dengue virus (DENV) is endemic. Dengue and Zika viruses are of the same family, share a vector and may interact competitively or synergistically through human immune responses. We examine dengue incidence data from Brazil and Colombia from before, during, and after the Zika epidemic. We find evidence that dengue incidence was atypically low in 2017 in both Brazil and Colombia. We investigate whether Zika incidence at the state or department level is associated with changes in dengue incidence and find mixed results. We use simulations to investigate expected impact of cross-protection or enhancement between dengue and Zika. Our simulations show that regardless of the mechanism, low periods of dengue incidence are followed by a resurgence in dengue cases. It is therefore likely that countries currently experiencing low levels of dengue incidence will experience large dengue seasons in the near future. By considering multiple combinations of DENV and ZIKV reproduction numbers, we demonstrate that the mixed results of our statistical models are not entirely unexpected. Correlations in DENV and ZIKV reproduction number could contribute to complicating or masking an association between their case counts.